Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
Conditions: Blasts 5 Percent or More of Bone Marrow Nucleated Cells; Central Nervous System Neoplasm; ETV6 Gene Rearrangement; Infantile Fibrosarcoma; NTRK1 Fusion Positive; NTRK1 Gene Rearrangement; NTRK2 Fusion Positive; NTRK2 Gene Rearrangement; NTRK3 Fusion Positi ve; NTRK3 Gene Rearrangement; Recurrent Acute Leukemia; Refractory Acute Leukemia; Solid Neoplasm Intervention: Drug: Larotrectinib Sponsors: Children's Oncology Group; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials